REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia

Status:
Active, not recruiting

Trial end date:
2021-09-30

Target enrollment:

Participant gender:

To assess the safety and efficacy of CK0802 in treatment of patients with COVID-19 induced moderate-to-severe PNA-ARDS.

Phase 1

Cellenkos, Inc.